Listen Now

Recent years have seen a boom in biometric security systems—identification measures based on a person’s individual biology—from unlocking smartphones, to automating border controls. As this technology becomes more prevalent, some cybersecurity researchers are worried about how secure biometric data is—and the risk of spoofs. If generative AI becomes so powerful and easy-to-use that deepfake audio and video could hack into our security systems, what can be done?  Bruce Schneier, a security technologist at Harvard University and the author of “A Hacker’s Mind”, explores the cybersecurity risks associated with biometrics, and Matthias Marx, a security researcher, discusses the consequences of bad actors obtaining personal data. If artificial intelligence could overcome security systems, human implants may be used as authentication, according to Katina Michael, a professor at Arizona State University. Plus, Joseph Lindley, a design academic at Lancaster University, proposes how security systems can be better designed to avoid vulnerabilities. To think about practical solutions, Scott Shapiro, professor at Yale Law School and author of “Fancy Bear Goes Phishing”, puts generative AI into the wider context of cybersecurity. Finally, Tim Cross, The Economist’s deputy science editor, weighs up the real-world implications of our thought experiment. Kenneth Cukier hosts. Learn more about detecting deepfakes at economist.com/detecting-deepfakes-pod, or listen to all of our generative AI coverage at economist.com/AI-pods. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Clinical trials are the gold standard for testing the safety and efficacy of a treatment or drug, and a keystone in modern medicine. But their grinding timelines and skyrocketing price tags are hindering development and, ultimately, costing lives. Natasha Loder, The Economist’s health editor, asks Sir Martin Landray, the boss of Protas, a clinical-trial organisation, what can be learned from his pioneering RECOVERY covid-19 trial. Euan Ashley, a cardiologist at Stanford University, explains how to use wearable technology to conduct wholly digital clinical trials. Plus, Alejandro Frangi of the University of Leeds says virtual clinical trials that use computers to model medical interventions can save time and money. Alok Jha, The Economist's science and technology editor, hosts. We would love to hear from you. Please fill out our listener survey at economist.com/babbagesurvey. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Antimicrobial resistance killed over a million people in 2019. That figure is expected to rise to ten million by 2050. Antibiotics remain vital to modern medicine, but this hidden pandemic of drug-resistant superbugs is driving scientists to explore possible alternatives. One type of therapy in particular is attracting serious scientific interest: bacteriophages.  Phages are viruses that can destroy bacteria. In the 1920s, phage therapies were used widely against infections, but much of the world abandoned the idea following the discovery of penicillin. Some parts of the former Soviet Union, though, have continued to use phage therapies. What can governments and international companies learn from this medicine? Gilead Amit, The Economist’s science correspondent, travels to the Eliava Institute in Tbilisi, Georgia to find out how phage therapies have been used there over the last century. He speaks to the director, Mzia Kutateladze, head of phage production, Vakho Pavlenishvili, and from the therapy centre: Davit Sturia, Lia Nadareishvili and Lana Abesadze. Barry Rud, a Canadian patient attending the clinic, discusses his experience. Steffanie Strathdee, who leads phage research at the University of California, San Diego, explains the renewed international interest in bacteriophages. Alok Jha, The Economist’s science and technology editor, hosts. We would love to hear from you. Please fill out our listener survey at economist.com/babbagesurvey. The Economist is also seeking applications for the 2023 Richard Casement internship. The successful candidate will spend three months with us in London writing about science and technology. More details here: economist.com/casement2023. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

The use of drones in the war in Ukraine has been increasing. Unmanned vehicles capture battlefield images, relay co-ordinates, and strike targets in Ukraine and even Russia. Whether purpose-built military devices or off-the-shelf civilian technology, the drones are having an outsized impact. How are they influencing battles? And what do they mean for the future of warfare? Oliver Carroll, our correspondent in Ukraine, explores the purpose and effectiveness of drones in the war. Ulrike Franke of the European Council on Foreign Relations explains the potential that drone technology offers to armies. Plus, The Economist’s Benjamin Sutherland travels to Kyiv, to investigate how engineers in underground workshops are tinkering with consumer drones and turning them into military machines. Alok Jha, The Economist’s science and technology editor, hosts.   If you love Babbage, why not work with us? We’re hiring for an Assistant Audio Producer to work on the show. Apply by May 15th. The Economist is also seeking applications for the 2023 Richard Casement internship. The successful candidate will spend three months with us in London writing about science and technology. More details here: economist.com/casement2023. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

The vast majority of the energy used on Earth comes from fossil fuels. But as governments enact climate-friendly policies, electric grids need to be decarbonised, by using renewable-energy sources. And much more electricity needs to be generated too—to power transport, homes and heavy industry. Despite its urgency, redesigning electric grids is both a political and technological challenge. How can such a revolution happen? Host Kenneth Cukier explores the mechanics of how electric grids work and how to upgrade them with The Economist’s Hal Hodson. Hal travels to Drax, a power station in the north of England, to visualise this supersized circuit with Bruce Heppenstall, the plant’s director. Plus, Hal asks Gerhard Salge, the chief technology officer of Hitachi Energy, how the latest generation of high voltage direct current cables will transform energy systems. If you love Babbage, why not work with us? We’re hiring for an Assistant Audio Producer to work on the show. Apply by May 15th. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Since the launch of OpenAI’s ChatGPT almost six months ago, little else has occupied the minds of technologists. Generative artificial intelligence—capable of producing media like text, images and audio in response to prompts—seems to be improving every day, with many technology companies developing and releasing their own competing systems. As the AI revolution accelerates, the technology is being used in ever more creative ways, companies are discovering its potential, causing unease among many content-creators and white-collar professionals, whose jobs seem to be at risk. The story of automation changing the world of work is not a new one. But the speed, the visibility and the hype surrounding generative AI can seem alarming. How worrying is it? The Economist’s Abby Bertics and Arjun Ramani explain how large language models work, the risk posed by the technology—and what to do about it. Callum Williams, our senior economics writer, ponders the potential for economic disruption as generative AI enters the workplace. Plus, Tom Standage, The Economist’s deputy editor explores the question of regulating this emerging technology without hindering innovation. Kenneth Cukier hosts. Listen to all of our coverage of the artificial intelligence revolution at economist.com/AI-pods. If you love Babbage, why not work with us? We’re hiring for an Assistant Audio Producer to work on the show. Apply by May 15th. Hosted on Acast. See acast.com/privacy for more information.

Twenty years ago, the Human Genome Project was completed. It unveiled a mostly complete sequence of the 3 billion pairs of building blocks that make up the code within every set of human chromosomes. These are the instructions that create humans. Almost all of human biology research uses the Human Genome Project’s findings in some way, from understanding why some people are more likely to develop diseases than others, to uncovering the secrets of our ancestors and evolution. But for genomics to become a part of everyday medicine, paving the way for personalised medicines, the hard work is still ahead. Natasha Loder, The Economist’s health editor and Geoff Carr, our senior editor for science and technology, reflect on the completion of the Human Genome Project in the early 2000s and the gaps that still remain. Natasha also visits the Wellcome Sanger Institute, to explore the next frontiers for genomics in medicine—she meets the outgoing director, Mike Stratton; the incoming director, Matt Hurles; and the boss of the European Bioinformatics Institute, Ewan Birney. Plus, Mathew Davies, an engineer at the Sanger Institute, and his team, discuss the challenges with storing and processing vast amounts of sequencing data. Alok Jha, The Economist’s science and technology editor, hosts. To dive deeper on genomics, find our recent episode from the Third International Summit on Human Genome Editing, or explore the power of gene therapies, and also an explainer on how genomic sequencing works. If you love Babbage, why not work with us? We’re hiring for an Assistant Audio Producer to work on the show. Apply by May 15th. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

This week, the European Space Agency is expected to launch a spacecraft towards Jupiter and three of its icy moons—Ganymede, Europa and Callisto. The JUICE mission will carry ten instruments to the outer solar system and will hunt for water, a heat source and organic material—the ingredients that scientists think are needed for life. It is hoped the results that come from JUICE, and a similar NASA mission, Europa Clipper, will give us scientists a clearer view of whether life exists beyond planet Earth.  Tim Cross, The Economist’s deputy science editor, explains why missions to the Jovian system represent a shift away from Mars, to hunt for extraterrestrial life. Plus, Jason Hosken, our producer, visits Imperial College London to find out how the JUICE magnetometer works, with engineers Patrick Brown and Richard Baughen. He also asks Michele Dougherty, the instrument’s principal investigator, about the mission’s scientific aims. Alok Jha, The Economist’s science and technology editor, hosts. This is the second episode on the grand scientific quest to search for life beyond Earth. Last week, we asked exoplanet hunter and Nobel laureate, Didier Queloz, how to start answering one of the universe’s most intriguing questions. Listen at economist.com/queloz-pod or on your podcast app. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

As they stare up into the night sky, astronomers have long wondered whether life exists elsewhere in the universe. For decades, the hunt for extraterrestrial life has focused on Mars, Venus and even on the various moons of our solar system. But in 1995, that search entered a new phase, when Didier Queloz and Michel Mayor found the first clear evidence of a planet orbiting another star: 51 Pegasi b. Since then, more than 5,000 exoplanets have been found. This week, Alok Jha asks Nobel laureate Dider Queloz, how the “exoplanet revolution” has influenced the search for life elsewhere. Dider Queloz is the founding director of the Center for the Origin and Prevalence of Life at ETH Zurich and the director of the Leverhulme Centre for Life in the Universe at the University of Cambridge. We also hear from Emily Mitchell, the co-director of the Leverhulme Centre, on what an international collaboration of scientists called the “Origins Federation” has set out to study. Alok Jha, The Economist’s science and technology editor, hosts. This is the first of two episodes on the grand scientific quest to search for life beyond Earth. Next time, we’ll explore the European Space Agency’s mission to Jupiter’s icy moons: JUICE. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Imagine a power source that produces hardly any waste and is carbon-free. That’s the tantalising promise of controlled nuclear fusion, which physicists have been trying to achieve for 70 years. It is a simulacrum of the process that powers the sun, colliding atomic nuclei of various sorts to release huge amounts of energy.  Fusion research was once the provenance of governments and national laboratories, but now private companies are getting in on the act. Dozens of them are exploring different ways to create the extreme conditions needed to achieve fusion here on Earth. And, contrary to the old joke that fusion power is thirty years away, and always will be, some of them think they can get there in a decade. Fernanda Rimini, an experimental fusion scientist with the UK Atomic Energy Authority, explains how nuclear fusion works. Geoff Carr, The Economist’s science and technology editor, explores why fusion is coming back into fashion for private companies. Geoff also speaks to Bob Mumgaard of Commonwealth Fusion Systems, Warrick Matthews of Tokamak Energy and Nick Hawker of First Light Fusion. Plus, Stephen Cowley, the director of the Princeton Plasma Physics Laboratory assesses how helpful the latest private fusion ventures are in advancing the field. Alok Jha hosts. Hosted on Acast. See acast.com/privacy for more information.

OpenAI's ChatGPT, an advanced chatbot, has taken the world by storm, amassing over 100 million monthly active users and exhibiting unprecedented capabilities. From crafting essays and fiction to designing websites and writing code, you’d be forgiven for thinking there’s little it can’t do.  Now it’s had an upgrade. GPT-4 has even more incredible abilities, it can take in photos as an input, and deliver smoother, more natural writing to the user. But it also hallucinates, throws up false answers, and remains unable to reference any world events that happened after September 2021. Seeking to get under the hood of the Large Language Model that operates GPT-4, host Alok Jha speaks with Maria Laikata, a professor in Natural Language Processing at Queen Mary University of London. We put the technology through its paces with The Economist’s tech-guru Ludwig Seigele, and even run it through something like a Turing Test to give an idea of whether it could pass for human-level-intelligence.  An Artificial General Intelligence is the ultimate goal of AI research, so how significant will GPT-4 and similar technologies be in the grand scheme of machine intelligence? Not very, suggests Gary Marcus, expert in both AI and human intelligence, though they will impact all of our lives both in good and bad ways.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

A new class of drugs for weight loss have become available and are showing promising results. That’s welcome news, as a recent report estimates that half of the world’s population is expected to be overweight or obese by 2035. Obesity is a disease which can lead to serious health complications–and most previous attempts at treating it have proven futile. Can the new weight-loss drugs turn the tide against this global threat? Louise Baur, president of the World Obesity Federation crunches the numbers on the global impact of overweight and obesity. Stephan Guyenet, a neurobiologist and author of “The Hungry Brain”, explains the neurological and genetic factors that influence weight gain. Chris van Tulleken, an infectious diseases doctor at University College London and author of the upcoming book “Ultra-Processed People”, explores how the modern diet is contributing to the obesity epidemic–and other health problems. Plus, host Alok Jha asks Natasha Loder, The Economist’s health editor, how important the new skinny jabs are in the fight against obesity. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

The Third International Summit on Human Genome Editing was held this week in London. It was the first such meeting since 2018, when a Chinese researcher announced that he had created the world’s first genetically edited babies—a move that was roundly condemned at the time. Host Alok Jha and Natasha Loder, The Economist’s health editor, report from the conference to explore the exciting future—and knotty challenges—of the world that gene-editing therapies could create. Robin Lovell-Badge, a leading scientist at the Francis Crick Institute in London and the organiser of the summit, explains how genome-editing technology has rapidly advanced in recent years. Claire Booth, a professor of gene therapy and paediatric immunology at Great Ormond Street Hospital and University College London discusses the hopes of gene-editing treatments. Plus, Kelly Ormond, a bioethicist from ETH-Zurich, explores the ethical dilemmas that are raised by the technology, and Filippa Lentzos of King’s College London, explains why human genome editing presents potential biosecurity risks. Listen to previous episodes of “Babbage” on the topic: the gene therapy revolution and an interview with Jennifer Doudna, the pioneer of CRISPR-Cas9 technology.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

There is a worrying amount of fraud in medical research. As many as one in 50 research papers may be unreliable because of fabrication, plagiarism or serious errors. Fabricated data can influence the guidelines which doctors use to treat patients. Misguided clinical guidelines could cause serious illness and death in patients. Fraudulent studies can also influence further research programmes—recent findings suggest that manipulated images may have resulted in scientists wasting time and money following blind alleys in Alzheimer’s research for decades. What can be done to combat scientific malpractice?  Dorothy Bishop, a retired professor of psychology at the University of Oxford, explores the motivation behind fraudsters in research. John Carlisle, an anaesthetist and an editor of the journal Anaesthesia, explains the impact of fraud and how to detect it in research papers. Also, Elisabeth Bik, a former microbiologist and a full-time scientific image detective, discusses the consequences of whistle-blowing on both sleuths and the fraudsters. Plus, The Economist’s health-care correspondent, Slavea Chankova, investigates how to overcome the worrying unwillingness on all sides to do anything about fraud in research. Alok Jha hosts. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Over the past few years, hundreds of rugby players have launched class-action lawsuits against the sport’s governing bodies, accusing them of failing to do enough to protect players from head injuries. They say that repeated blows to the head, sustained through years of playing rugby, or other sports, have caused neurodegenerative conditions like dementia, motor neurone and Parkinson’s diseases. But can scientific evidence prove a link between contact sports and these brain conditions?  Alix Popham, a Welsh former professional rugby player, tells his story of head injuries on the pitch and his desired outcomes from the lawsuits. Plus, Lauren Pulling, who runs the Drake Foundation, explains the current state of neuroscientific research and what further studies are needed to investigate the connection. Alok Jha hosts with Natasha Loder, The Economist’s health editor, and Georgia Banjo, our Britain correspondent.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Over the past 18 months, the largest-ever recorded avian influenza outbreak has decimated bird populations around the world. But recently bird flu has spread to mammals. Last week, Peru reported the deaths of 585 sea lions. If the virus has mutated to enable mammal-to-mammal transmission, that could be an intermediate step towards human-to-human transmission. How worrying is this threat? Susan Davies, CEO of the Scottish Seabird Centre, describes how the H5N1 avian flu has affected populations of wild birds. Ian Brown of Britain’s Animal and Plant Health Agency explains why the dynamics of this outbreak are concerning scientists. Plus, we ask Marion Koopmans, head of viroscience at Erasmus MC, why she’s more worried than ever about a human influenza pandemic. The Economist’s Slavea Chankova also compares the influenza threat to the covid-19 pandemic. Do we have enough tools in our arsenal? Alok Jha hosts.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Engineers have spent decades trying to create functional humanoid robots, which look and act like humans. But these machines, which combine complex mechanics with generative artificial intelligence models, like ChatGPT, are finally coming-of-age. Are they good enough to sustain a human-like conversation, though? Host Alok Jha travels to Cornwall to meet Ameca, a robot made by Engineered Arts. Will Jackson, the company’s boss, explains how the technology behind Ameca works and the advantages of having robots that look and behave like people. Plus, Paul Markillie, The Economist’s innovation editor, assesses the state of the field and how to prepare for the rollout of humanoid robots.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Alcohol is the most widely used drug in the world, but it is also the cause of three million deaths each year and has been linked to many other long-term illnesses. In addition, the loss of productivity due to hangovers has an outsized impact on some economies. People still want to have a good time, though, and innovators are dreaming up ways to enjoy the effects of alcohol, without the costs. Jason Hosken, our producer, visits Brixton Brewery to speak to co-founders Jez Galaun and Xochitl Benjamin about the rise of alcohol-free beer. Natasha Loder, The Economist’s health editor, investigates the herbal drinks that claim to mimic the effects of alcohol. Plus, David Nutt, a professor at Imperial College London explains how alcohol affects the brain and why his synthetic alcohol could reduce excessive drinking and end hangovers forever.  For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Three firms are racing to become the first private company to land on the Moon. The potential commercial opportunities range from mining lunar resources to establishing a human base with communications infrastructure. But the commercialisation of the Moon raises tricky questions about who owns Earth’s closest neighbour. Steve Altemus, CEO of Intuitive Machines, explains what he hopes his company’s missions will achieve, while Ian Jones of Goonhilly Earth Station describes how the blossoming private space sector is boosting the economy. And Dhara Patel, an expert at Britain’s National Space Centre, explores how the international community has attempted to govern space. Alok Jha hosts with Tom Standage, The Economist’s deputy editor. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Digital fakery, from the latest generation of deepfakes to lower-tech trickery, threatens to erode trust in societies and can prevent justice from being served. But how can technology be used to both detect deepfakes and authenticate real images? Patrick Traynor, a professor at the University of Florida, explains a novel method to expose audio generated by artificial intelligence. Ilke Demir of Intel Labs demonstrates how to spot visual fakery by analysing colour changes in the face. Plus, The Economist’s Benjamin Sutherland investigates the flipside of deepfakes: how to prove that footage is real. And Wendy Betts of eyeWitness to Atrocities explains how her technology is being used as evidence for war crimes. Alok Jha hosts. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.